NanoVibronix, Inc. (56R0.F)
| Previous close | 5.8200 |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | N/A - N/A |
| 52-week range | 5.8200 - 5.8200 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 0 |
| Beta (5Y monthly) | 1.30 |
| PE ratio (TTM) | -0.00 |
| EPS (TTM) | -3.4900 |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan
ELMSFORD, N.Y., May 22, 2024--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The "pilot" phase of the study is the first component of the broader study.
Business WireNanoVibronix Issues Letter to Stockholders
TYLER, Texas, May 16, 2024--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter of 2024 and recent business developments.
Business WireNanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield
TYLER, Texas, May 14, 2024--NanoVibronix, Inc. (Nasdaq: NAOV) ("NanoVibronix," or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with CB Medical, LLC ("CB Medical") for the sale and distribution of the Company’s UroShield.
